Bristol-Myers stock gains on new Krazati label (NYSE:BMY)
2024-06-21
hapabapa The U.S. Food and Drug Administration (FDA) on Friday greenlighted Bristol Myers Squibb’s (NYSE:BMY) marketing application to expand the label for its lung cancer therapy Krazati to include patients with colorectal cancer. Accordingly, Krazati, added to Bristol Myers’ (BMY) portfolio with its $4.8B Mirati acquisition this year, will beContinue Reading